Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 41 EP651 | DOI: 10.1530/endoabs.41.EP651

1Department of Endocrinology, Metaxa Anticancer Hospital, Pireaus, Athens, Greece; 2Department of Gynecology, Metaxa Anticancer Hospital, Pireaus, Athens, Greece.

Introduction: Virilizing tumors are rare, but frequent cause of virilization in postmenopausal women.

Case report: A 62-year-old postmenopausal woman presented with a rapid onset of hirsutism with increased terminal hair growth, particular on chin and abdomen, frontal male pattern balding in the last 5 months. Physical examination revealed a low-pitched, deepened voice and clitoromegaly. The Ferriman–Gallwey score was 18. Laboratory evaluation: Testosterone: 11.2 ng/ml (nr for women 0.07–0.65), DHEAS 154.4 μg/dl (24.6–182.3), 17OHP 0.5 ng/ml (0.19–0.71), Δ4A 1.4 ng/ml (0.3–3.7), FSH 11.6 IU/l (27.7–93.3), LH 1.6 IU/l (14.4–52.8), PRL 6 ng/ml (1.9–17.9), E2 91.7 pg/ml (6–53). On a 48-h low-dose (2 mg/day) dexamethasone-suppression test, testosterone showed only a 24% reduction from baseline, while DHEAS was practically unchanged. A pelvis MRI scanning revealed normal adrenal glands and enlargement of the right ovary with an echogenic solid mass measuring 3.6×3.7×4 cm and a laparoscopic right salpingo-oophorectomy was performed. Histopathology revealed a Leydig cell tumor with no malignant features.

Conclusions: Hyperandrogenism and especially virilization in menopausal women has to be investigated thoroughly, since the percentage of virilizing tumors of adrenal or ovarian origin is much higher in menopause than during reproductive age. Ovarian virilizing tumors are usually benign and the treatment of choice is surgical removal.

Article tools

My recent searches

No recent searches.